GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

46.48 -0.55 (-1.18%)

Delayed Quote Updated: 12:38 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

45 46 Next >

Electronic Arts Posts Upbeat Earnings, Joins Mattel, Johnson Controls, Mueller Water Products And Other Big Stocks Moving Higher On Wednesday ↗

February 05, 2025

Via Benzinga

GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 Billion Stock Buyback, Raises Long-Term Annual Sales Forecast To Over $50 Billion ↗

February 05, 2025

GSK's Q4 sales hit $10.40 billion, topping estimates. Specialty Medicines grew 14%, while vaccines declined. The company announced a $2.5 billion share buyback plan.

Via Benzinga

Earnings Scheduled For February 5, 2025 ↗

February 05, 2025

Via Benzinga

RFK Jr. Clears A Key Hurdle To Head Up HHS. Why His Nomination Is A Biotech Black Box. ↗

February 04, 2025

RFK Jr. cleared a key hurdle Tuesday after the Senate Finance Committee voted along party lines in favor of his nomination.

Via Investor's Business Daily

The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings ↗

January 29, 2025

The Senate will meet Wednesday to start the confirmation hearing process for Robert F. Kennedy Jr.

Via Investor's Business Daily

Moderna, Pfizer Surge Amid CDC-WHO Split And Bird Flu; RFK Jr. Nomination Looms — A Recipe For The Perfect Storm? ↗

January 28, 2025

The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health Organization on Monday, marking a dramatic acceleration of President Donald...

Via Benzinga

Topics Government

Trump Administration Halts All Communications From The Centers For Disease Control As Bird Flu Spreads ↗

January 24, 2025

As the bird flu virus continues to spread through the United States, the Trump administration on Tuesday ordered all communications from the Centers for Disease Control and Prevention to stop.

Via Benzinga

Topics Government

After a Reset Year, Is Moderna Stock Poised for a Comeback?

January 22, 2025

Moderna had a rough 2024 and is starting 2025 with lowered forecasts, but is focused on getting 10 FDA approvals in the next three years. Is now time to buy?

Via MarketBeat

Bird Flu Update: First Commercial Case In Georgia, Moderna Receives $590 Million To Develop Vaccine ↗

January 21, 2025

According to the latest data from the Centers for Disease Control, the current bird flu outbreak has caused 67 human cases of bird flu in the U.S. and one death associated with the virus.

Via Benzinga

Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus

January 22, 2025

From FN Media Group LLC

Via GlobeNewswire

Europe Drug Regulator Expands GSK's Jemperli/Chemo Combo To Adult Patients With Advanced Endometrial Cancer ↗

January 21, 2025

GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant trial results.

Via Benzinga

Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt ↗

January 17, 2025

Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company.

Via Benzinga

Topics Government

January 17, 2025

HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027.

Via Benzinga

Topics Economy

Bird Flu Raising Red Flags Among Health Officials, CDC Urges Faster Testing ↗

January 16, 2025

The CDC issued a health advisory Thursday recommending that hospitalized patients who have tested positive for influenza be tested for the bird flu virus within 24 hours.

Via Benzinga

Will GSK’s Seasonal Strength And Oncology Focus Drive Gains? ↗

January 16, 2025

A look at GSK’s long-term price action reveals critical levels on the monthly chart.

Via Talk Markets

Topics Stocks / Equities

GSK Highlights New Approvals, Vaccine Momentum At JPMorgan Healthcare Conference ↗

January 15, 2025

GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.

Via Benzinga

Moderna Has Lost 94% Of Its Value Over Four Years. Is It A Sell? ↗

January 14, 2025

Shares hit another skid on Jan. 13 when the company cut its guidance for 2024 and 2025.

Via Investor's Business Daily

GSK To Buy US-Based Stomach Cancer Drug Developer For Over $1 Billion ↗

January 13, 2025

GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early treatment stages.

Via Benzinga

GSK Enters Agreement to Acquire IDRx, Inc.

January 13, 2025

From GSK plc and IDRx, Inc.

Via Business Wire

Why CureVac (CVAC) Shares Are Volatile ↗

January 10, 2025

CureVac shares have been volatile over the past week, gaining some 25%. The stock has seen increased trading volume following the U.S.'s first human death from H5N1 bird flu.

Via Benzinga

Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies ↗

January 08, 2025

Bird flu has severely impacted poultry farms and cattle herds across 16 states, marking the worst outbreak of its kind.

Via Benzinga

Topics ETFs

Pfizer And GSK's RSV Vaccines Safety Labels Updated, FDA Adds Warning For Rare Neurological Disorder ↗

January 08, 2025

FDA updates safety labels for Pfizer's Abrysvo and GSK's Arexvy RSV vaccines, citing increased Guillain-Barré syndrome risk. Study estimates 7-9 excess GBS cases per million doses.

Via Benzinga

US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally ↗

January 07, 2025

The Louisiana Department of Health on Monday reported the first human death in the U.S. related to the H5N1 bird flu virus. The CDC is also reporting high levels of acute respiratory illnesses...

Via Benzinga

GSK's Sinus Disease Drug Secures Approval In China ↗

January 03, 2025

China approves GSK's Nucala for chronic rhinosinusitis with nasal polyps, adding to its existing uses in asthma and other eosinophilic conditions.

Via Benzinga

Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook

December 26, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:GSK),(NASDAQ:AZN),(NYSE:ABBV),(NASDAQ:CRDF) EQNX::TICKER_END

Via FinancialNewsMedia

Pfizer's Progress on C. diff Vaccine and Pneumococcal Shot Wins Analyst Conviction ↗

December 23, 2024

Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in Phase 2. Data expected in 2025.

Via Benzinga

Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services ↗

December 19, 2024

U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending.

Via Benzinga

Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook

December 26, 2024

From FN Media Group LLC

Via GlobeNewswire

Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

December 18, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:PFE),(NYSE:GSK),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

December 18, 2024

From FN Media Group LLC

Via GlobeNewswire

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

45 46 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.